RNAi for Therapeutic-Europe Market Status and Trend Report 2013-2023
Report Summary
RNAi for Therapeutic-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on RNAi for Therapeutic industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of RNAi for Therapeutic 2013-2017, and development forecast 2018-2023
Main market players of RNAi for Therapeutic in Europe, with company and product introduction, position in the RNAi for Therapeutic market
Market status and development trend of RNAi for Therapeutic by types and applications
Cost and profit status of RNAi for Therapeutic, and marketing status
Market growth drivers and challenges
The report segments the Europe RNAi for Therapeutic market as:
Europe RNAi for Therapeutic Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe RNAi for Therapeutic Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
siRNA
miRNA
shRNA
Europe RNAi for Therapeutic Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Cancer
Cardiovascular
HBV
Other
Europe RNAi for Therapeutic Market: Players Segment Analysis (Company and Product introduction, RNAi for Therapeutic Sales Volume, Revenue, Price and Gross Margin):
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead Research
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
Miragen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Arcturus Therapeutics
Ariz Biopharma
Celsion Corporation
Ascletis Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
RNAi for Therapeutic-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on RNAi for Therapeutic industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of RNAi for Therapeutic 2013-2017, and development forecast 2018-2023
Main market players of RNAi for Therapeutic in Europe, with company and product introduction, position in the RNAi for Therapeutic market
Market status and development trend of RNAi for Therapeutic by types and applications
Cost and profit status of RNAi for Therapeutic, and marketing status
Market growth drivers and challenges
The report segments the Europe RNAi for Therapeutic market as:
Europe RNAi for Therapeutic Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe RNAi for Therapeutic Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
siRNA
miRNA
shRNA
Europe RNAi for Therapeutic Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Cancer
Cardiovascular
HBV
Other
Europe RNAi for Therapeutic Market: Players Segment Analysis (Company and Product introduction, RNAi for Therapeutic Sales Volume, Revenue, Price and Gross Margin):
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead Research
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
Miragen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Arcturus Therapeutics
Ariz Biopharma
Celsion Corporation
Ascletis Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF RNAI FOR THERAPEUTIC
1.1 Definition of RNAi for Therapeutic in This Report
1.2 Commercial Types of RNAi for Therapeutic
1.2.1 siRNA
1.2.2 miRNA
1.2.3 shRNA
1.3 Downstream Application of RNAi for Therapeutic
1.3.1 Cancer
1.3.2 Cardiovascular
1.3.3 HBV
1.3.4 Other
1.4 Development History of RNAi for Therapeutic
1.5 Market Status and Trend of RNAi for Therapeutic 2013-2023
1.5.1 Europe RNAi for Therapeutic Market Status and Trend 2013-2023
1.5.2 Regional RNAi for Therapeutic Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of RNAi for Therapeutic in Europe 2013-2017
2.2 Consumption Market of RNAi for Therapeutic in Europe by Regions
2.2.1 Consumption Volume of RNAi for Therapeutic in Europe by Regions
2.2.2 Revenue of RNAi for Therapeutic in Europe by Regions
2.3 Market Analysis of RNAi for Therapeutic in Europe by Regions
2.3.1 Market Analysis of RNAi for Therapeutic in Germany 2013-2017
2.3.2 Market Analysis of RNAi for Therapeutic in United Kingdom 2013-2017
2.3.3 Market Analysis of RNAi for Therapeutic in France 2013-2017
2.3.4 Market Analysis of RNAi for Therapeutic in Italy 2013-2017
2.3.5 Market Analysis of RNAi for Therapeutic in Spain 2013-2017
2.3.6 Market Analysis of RNAi for Therapeutic in Benelux 2013-2017
2.3.7 Market Analysis of RNAi for Therapeutic in Russia 2013-2017
2.4 Market Development Forecast of RNAi for Therapeutic in Europe 2018-2023
2.4.1 Market Development Forecast of RNAi for Therapeutic in Europe 2018-2023
2.4.2 Market Development Forecast of RNAi for Therapeutic by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of RNAi for Therapeutic in Europe by Types
3.1.2 Revenue of RNAi for Therapeutic in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of RNAi for Therapeutic in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of RNAi for Therapeutic in Europe by Downstream Industry
4.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in Major Countries
4.2.1 Demand Volume of RNAi for Therapeutic by Downstream Industry in Germany
4.2.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in United Kingdom
4.2.3 Demand Volume of RNAi for Therapeutic by Downstream Industry in France
4.2.4 Demand Volume of RNAi for Therapeutic by Downstream Industry in Italy
4.2.5 Demand Volume of RNAi for Therapeutic by Downstream Industry in Spain
4.2.6 Demand Volume of RNAi for Therapeutic by Downstream Industry in Benelux
4.2.7 Demand Volume of RNAi for Therapeutic by Downstream Industry in Russia
4.3 Market Forecast of RNAi for Therapeutic in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF RNAI FOR THERAPEUTIC
5.1 Europe Economy Situation and Trend Overview
5.2 RNAi for Therapeutic Downstream Industry Situation and Trend Overview
CHAPTER 6 RNAI FOR THERAPEUTIC MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of RNAi for Therapeutic in Europe by Major Players
6.2 Revenue of RNAi for Therapeutic in Europe by Major Players
6.3 Basic Information of RNAi for Therapeutic by Major Players
6.3.1 Headquarters Location and Established Time of RNAi for Therapeutic Major Players
6.3.2 Employees and Revenue Level of RNAi for Therapeutic Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 RNAI FOR THERAPEUTIC MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Alnylam Pharmaceuticals
7.1.1 Company profile
7.1.2 Representative RNAi for Therapeutic Product
7.1.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
7.2 Arbutus Biopharma (Tekmira)
7.2.1 Company profile
7.2.2 Representative RNAi for Therapeutic Product
7.2.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arbutus Biopharma (Tekmira)
7.3 Arrowhead Research
7.3.1 Company profile
7.3.2 Representative RNAi for Therapeutic Product
7.3.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arrowhead Research
7.4 Dicerna Pharmaceuticals
7.4.1 Company profile
7.4.2 Representative RNAi for Therapeutic Product
7.4.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals
7.5 Mirna Therapeutics
7.5.1 Company profile
7.5.2 Representative RNAi for Therapeutic Product
7.5.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Mirna Therapeutics
7.6 Quark Pharmaceuticals
7.6.1 Company profile
7.6.2 Representative RNAi for Therapeutic Product
7.6.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Quark Pharmaceuticals
7.7 RXi Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative RNAi for Therapeutic Product
7.7.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of RXi Pharmaceuticals
7.8 Silence Therapeutics
7.8.1 Company profile
7.8.2 Representative RNAi for Therapeutic Product
7.8.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silence Therapeutics
7.9 Benitec Biopharma
7.9.1 Company profile
7.9.2 Representative RNAi for Therapeutic Product
7.9.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Benitec Biopharma
7.10 Miragen Therapeutics
7.10.1 Company profile
7.10.2 Representative RNAi for Therapeutic Product
7.10.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Miragen Therapeutics
7.11 Sylentis
7.11.1 Company profile
7.11.2 Representative RNAi for Therapeutic Product
7.11.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sylentis
7.12 Gradalis
7.12.1 Company profile
7.12.2 Representative RNAi for Therapeutic Product
7.12.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Gradalis
7.13 Sirnaomics
7.13.1 Company profile
7.13.2 Representative RNAi for Therapeutic Product
7.13.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sirnaomics
7.14 Silenseed
7.14.1 Company profile
7.14.2 Representative RNAi for Therapeutic Product
7.14.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silenseed
7.15 Arcturus Therapeutics
7.15.1 Company profile
7.15.2 Representative RNAi for Therapeutic Product
7.15.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics
7.16 Ariz Biopharma
7.17 Celsion Corporation
7.18 Ascletis Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF RNAI FOR THERAPEUTIC
8.1 Industry Chain of RNAi for Therapeutic
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF RNAI FOR THERAPEUTIC
9.1 Cost Structure Analysis of RNAi for Therapeutic
9.2 Raw Materials Cost Analysis of RNAi for Therapeutic
9.3 Labor Cost Analysis of RNAi for Therapeutic
9.4 Manufacturing Expenses Analysis of RNAi for Therapeutic
CHAPTER 10 MARKETING STATUS ANALYSIS OF RNAI FOR THERAPEUTIC
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of RNAi for Therapeutic in This Report
1.2 Commercial Types of RNAi for Therapeutic
1.2.1 siRNA
1.2.2 miRNA
1.2.3 shRNA
1.3 Downstream Application of RNAi for Therapeutic
1.3.1 Cancer
1.3.2 Cardiovascular
1.3.3 HBV
1.3.4 Other
1.4 Development History of RNAi for Therapeutic
1.5 Market Status and Trend of RNAi for Therapeutic 2013-2023
1.5.1 Europe RNAi for Therapeutic Market Status and Trend 2013-2023
1.5.2 Regional RNAi for Therapeutic Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of RNAi for Therapeutic in Europe 2013-2017
2.2 Consumption Market of RNAi for Therapeutic in Europe by Regions
2.2.1 Consumption Volume of RNAi for Therapeutic in Europe by Regions
2.2.2 Revenue of RNAi for Therapeutic in Europe by Regions
2.3 Market Analysis of RNAi for Therapeutic in Europe by Regions
2.3.1 Market Analysis of RNAi for Therapeutic in Germany 2013-2017
2.3.2 Market Analysis of RNAi for Therapeutic in United Kingdom 2013-2017
2.3.3 Market Analysis of RNAi for Therapeutic in France 2013-2017
2.3.4 Market Analysis of RNAi for Therapeutic in Italy 2013-2017
2.3.5 Market Analysis of RNAi for Therapeutic in Spain 2013-2017
2.3.6 Market Analysis of RNAi for Therapeutic in Benelux 2013-2017
2.3.7 Market Analysis of RNAi for Therapeutic in Russia 2013-2017
2.4 Market Development Forecast of RNAi for Therapeutic in Europe 2018-2023
2.4.1 Market Development Forecast of RNAi for Therapeutic in Europe 2018-2023
2.4.2 Market Development Forecast of RNAi for Therapeutic by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of RNAi for Therapeutic in Europe by Types
3.1.2 Revenue of RNAi for Therapeutic in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of RNAi for Therapeutic in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of RNAi for Therapeutic in Europe by Downstream Industry
4.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in Major Countries
4.2.1 Demand Volume of RNAi for Therapeutic by Downstream Industry in Germany
4.2.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in United Kingdom
4.2.3 Demand Volume of RNAi for Therapeutic by Downstream Industry in France
4.2.4 Demand Volume of RNAi for Therapeutic by Downstream Industry in Italy
4.2.5 Demand Volume of RNAi for Therapeutic by Downstream Industry in Spain
4.2.6 Demand Volume of RNAi for Therapeutic by Downstream Industry in Benelux
4.2.7 Demand Volume of RNAi for Therapeutic by Downstream Industry in Russia
4.3 Market Forecast of RNAi for Therapeutic in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF RNAI FOR THERAPEUTIC
5.1 Europe Economy Situation and Trend Overview
5.2 RNAi for Therapeutic Downstream Industry Situation and Trend Overview
CHAPTER 6 RNAI FOR THERAPEUTIC MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of RNAi for Therapeutic in Europe by Major Players
6.2 Revenue of RNAi for Therapeutic in Europe by Major Players
6.3 Basic Information of RNAi for Therapeutic by Major Players
6.3.1 Headquarters Location and Established Time of RNAi for Therapeutic Major Players
6.3.2 Employees and Revenue Level of RNAi for Therapeutic Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 RNAI FOR THERAPEUTIC MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Alnylam Pharmaceuticals
7.1.1 Company profile
7.1.2 Representative RNAi for Therapeutic Product
7.1.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
7.2 Arbutus Biopharma (Tekmira)
7.2.1 Company profile
7.2.2 Representative RNAi for Therapeutic Product
7.2.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arbutus Biopharma (Tekmira)
7.3 Arrowhead Research
7.3.1 Company profile
7.3.2 Representative RNAi for Therapeutic Product
7.3.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arrowhead Research
7.4 Dicerna Pharmaceuticals
7.4.1 Company profile
7.4.2 Representative RNAi for Therapeutic Product
7.4.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals
7.5 Mirna Therapeutics
7.5.1 Company profile
7.5.2 Representative RNAi for Therapeutic Product
7.5.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Mirna Therapeutics
7.6 Quark Pharmaceuticals
7.6.1 Company profile
7.6.2 Representative RNAi for Therapeutic Product
7.6.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Quark Pharmaceuticals
7.7 RXi Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative RNAi for Therapeutic Product
7.7.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of RXi Pharmaceuticals
7.8 Silence Therapeutics
7.8.1 Company profile
7.8.2 Representative RNAi for Therapeutic Product
7.8.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silence Therapeutics
7.9 Benitec Biopharma
7.9.1 Company profile
7.9.2 Representative RNAi for Therapeutic Product
7.9.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Benitec Biopharma
7.10 Miragen Therapeutics
7.10.1 Company profile
7.10.2 Representative RNAi for Therapeutic Product
7.10.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Miragen Therapeutics
7.11 Sylentis
7.11.1 Company profile
7.11.2 Representative RNAi for Therapeutic Product
7.11.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sylentis
7.12 Gradalis
7.12.1 Company profile
7.12.2 Representative RNAi for Therapeutic Product
7.12.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Gradalis
7.13 Sirnaomics
7.13.1 Company profile
7.13.2 Representative RNAi for Therapeutic Product
7.13.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sirnaomics
7.14 Silenseed
7.14.1 Company profile
7.14.2 Representative RNAi for Therapeutic Product
7.14.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silenseed
7.15 Arcturus Therapeutics
7.15.1 Company profile
7.15.2 Representative RNAi for Therapeutic Product
7.15.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics
7.16 Ariz Biopharma
7.17 Celsion Corporation
7.18 Ascletis Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF RNAI FOR THERAPEUTIC
8.1 Industry Chain of RNAi for Therapeutic
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF RNAI FOR THERAPEUTIC
9.1 Cost Structure Analysis of RNAi for Therapeutic
9.2 Raw Materials Cost Analysis of RNAi for Therapeutic
9.3 Labor Cost Analysis of RNAi for Therapeutic
9.4 Manufacturing Expenses Analysis of RNAi for Therapeutic
CHAPTER 10 MARKETING STATUS ANALYSIS OF RNAI FOR THERAPEUTIC
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
